Study of Indomethacin Capsules to Treat Pain Following Bunionectomy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

462 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-02-29

Study Completion Date

2012-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether Indomethacin \[Test\] Capsules are safe and effective for the treatment of postoperative bunionectomy pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Indomethacin Capsules to Treat Pain Following Bunionectomy

NCT01626118

Study of Diclofenac Capsules to Treat Pain Following Bunionectomy

NCT01462435

Analgesic Efficacy Of Valdecoxib In Patients Following Bunion Surgery

NCT00653354

Pain, Post-surgical

COMPLETED PHASE3

Safety and Efficacy Study of COV155 for Post-operative Bunionectomy Pain

NCT01743625

Pain, Postoperative Bunion

COMPLETED PHASE3

A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery

NCT01789476

Acute Pain

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Indomethacin 40 mg TID

Group Type EXPERIMENTAL

Indomethacin

Intervention Type DRUG

40 mg TID capsules

Indomethacin 40 mg BID

Group Type EXPERIMENTAL

Indomethacin

Intervention Type DRUG

40 mg BID capsules

Indomethacin 20 mg TID

Group Type EXPERIMENTAL

Indomethacin

Intervention Type DRUG

20 mg TID capsules

Celecoxib 200 mg

Group Type ACTIVE_COMPARATOR

Celecoxib

Intervention Type DRUG

200 mg capsules

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Capsules

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Indomethacin

40 mg TID capsules

Intervention Type DRUG

Indomethacin

40 mg BID capsules

Intervention Type DRUG

Indomethacin

20 mg TID capsules

Intervention Type DRUG

Celecoxib

200 mg capsules

Intervention Type DRUG

Placebo

Capsules

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is male or female between 18 and 65 years of age
* For women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control
* Has undergone primary, unilateral, first metatarsal bunionectomy with no additional collateral procedures
* Patient must be willing to stay at the study site ≥ 72 hours

Exclusion Criteria

* Patient has hypersensitivity, allergy, or clinically significant intolerance to any medications to be used in the study, or related drugs
* Patient has a current disease or history of a disease that will impact the study or the patient's well-being
* Patient has used or intends to use any of the medications that are prohibited by the protocol
* Patient has a history of drug or alcohol abuse or dependence, or patient has a positive urine drug screen or alcohol breathalyzer test
* Patient has taken another investigational drug within 30 days prior to screening

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No